

# Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial

Jennifer M Ryan, Jennifer Fortune, Andrea Stennett, Cherry Kilbride, Grace Lavelle, Wendy Hendrie, Lorraine DeSouza, Mohammed Abdul, Debbie Brewin, Lee David, Nana Anokye, Christina Victor and Meriel Norris

## Abstract

**Background:** There is limited information regarding the safety, feasibility and acceptability of behaviour-change interventions to increase physical activity (PA) and reduce sedentary behaviour among people with multiple sclerosis (MS). Prior to evaluating efficacy, it is important to identify problems with feasibility and acceptability, which may undermine effectiveness.

**Objective:** To examine the safety, feasibility and acceptability of a behaviour-change intervention to increase PA and reduce sedentary behaviour among people with MS.

**Methods:** Sixty people received a 3-month intervention or usual care. Fatigue, pain and adverse events (AEs) were assessed. Feasibility and acceptability were explored through focus groups with physiotherapists and interviews with participants. Fidelity to intervention content, delivery skills, programme receipt and programme task were assessed.

**Results:** There was no difference in AE rate between groups ( $p = 0.965$ ). Fatigue and pain were not higher in the intervention group at 3 or 9 months. Therapists reported the intervention was feasible to deliver and fidelity was acceptable. Twenty-nine participants (97%) attended at least 75% of sessions. Participants found the intervention acceptable but suggested some amendments were required to intervention components.

**Conclusions:** The intervention was safe, feasible and acceptable. Although modifications are required to intervention components, the intervention warrants further evaluation in a future trial.

**Keywords:** Clinical trial, fatigue, multiple sclerosis, rehabilitation, pain

Date received: 8 January 2019; revised: 11 October 2019; accepted: 13 October 2019.

## Introduction

Physical activity (PA) and reduced sedentary behaviour are associated with milder disability, better mental health and less fatigue among people with multiple sclerosis (MS).<sup>1–3</sup> However, people with MS are insufficiently active and spend prolonged time in sedentary behaviour.<sup>4,5</sup> Behaviour-change interventions are a potential method for increasing PA and reducing sedentary behaviour in people with MS.

A recent meta-analysis concluded that behaviour-change interventions for people with MS improved

self-reported PA.<sup>6</sup> However, as self-reported PA is only weakly correlated with objectively measured PA in people with and without MS,<sup>7–9</sup> it is recommended that objective measures of PA and sedentary behaviour are used to determine the effectiveness of behaviour-change interventions.<sup>6,8</sup> Of four studies that assessed effects on objectively measured PA,<sup>6</sup> only one found a between-group difference in favour of the intervention immediately post-intervention but not at 6 months post-intervention.<sup>1</sup> One study has examined the effect of a behaviour-change intervention on self-reported sitting time in people with MS with positive

Multiple Sclerosis Journal

1–12

DOI: 10.1177/  
1352458519886231

© The Author(s), 2019.  
Article reuse guidelines:  
sagepub.com/journals-  
permissions

Correspondence to:

**JM Ryan**  
Department of Epidemiology  
and Public Health Medicine,  
Royal College of Surgeons in  
Ireland (RCSI), Beaux Lane  
House, Lower Mercer Street,  
Dublin 2, Ireland.

**jenniferryan@rcsi.com**  
**Jennifer M Ryan**  
Ageing Studies Theme,  
Institute of Environment,  
Health and Societies,  
Brunel University London,  
London, UK/Department of  
Epidemiology and Public  
Health Medicine, Royal  
College of Surgeons in  
Ireland (RCSI), Dublin,  
Ireland

**Jennifer Fortune**  
**Andrea Stennett**  
**Cherry Kilbride**  
**Grace Lavelle**  
**Lorraine DeSouza**  
**Christina Victor**  
**Meriel Norris**  
Ageing Studies Theme,  
Institute of Environment,  
Health and Societies, Brunel  
University London, London,  
UK

**Wendy Hendrie**  
MS Therapy Centre,  
Norwich, UK

**Mohammed Abdul**  
The Berkshire MS Therapy  
Centre, Reading, UK

**Debbie Brewin**  
**Lee David**  
Health Economics Theme,  
Institute of Environment,  
Health and Societies, Brunel  
University London, London,  
UK

**Nana Anokye**  
10 Minute CBT, Letchworth  
Garden City, UK

results.<sup>10</sup> However, as PA and sedentary behaviour are distinct concepts, and guidelines recommend both increasing PA and reducing sedentary behaviour for health benefits,<sup>11</sup> interventions targeting both PA and sedentary behaviour are required.

Prior to evaluating efficacy of such interventions, it is important to identify problems with feasibility, acceptability and fidelity to the intervention, which may undermine effectiveness. This is an important step in evaluating a complex intervention that can enable differentiation between true ineffectiveness and implementation failure,<sup>12</sup> and has not been well described in this context to date. Of the 14 studies included in the meta-analysis of behaviour-change interventions,<sup>6</sup> one reported fidelity to content<sup>13</sup> and another reported fidelity to delivery.<sup>14</sup> No study explored the feasibility of delivering behaviour-change interventions to change PA behaviour from the perspective of the intervention provider. Only two studies asked participants for feedback on the intervention, both using a questionnaire with open-ended questions.<sup>15,16</sup> In addition, the safety of behaviour-change interventions to change PA behaviour is unclear. Seven of the 14 studies did not mention adverse events (AEs),<sup>14,17–19</sup> five stated no AEs were recorded without providing information on how this was assessed,<sup>1,16,20</sup> one assessed AEs in the intervention group only,<sup>15</sup> and one reported related-AEs only.<sup>13</sup>

We therefore aimed to examine the safety, feasibility, acceptability and effects of a behaviour-change intervention to increase PA and reduce sedentary behaviour among people with MS and to explore the feasibility of conducting a larger trial to evaluate effectiveness.

### Materials and methods

We conducted a randomised controlled trial with parallel process evaluation comparing a physiotherapist-led behaviour-change intervention to usual care. Participants were recruited from an MS Therapy Centre in England, and the MS Society UK website from April–September 2017. Inclusion criteria were a self-reported diagnosis of MS, ability to independently walk within the home with or without a walking aid, relapse-free for the past 3 months, and free of unstable medical conditions such as unstable angina that would make it unsafe to participate in PA. Participants had to be able to travel to the centre, converse in English and have sufficient cognition to complete assessments and participate in the intervention. Exclusion criteria were pregnancy and ongoing participation in other trials.

Assessments were conducted at baseline, 3 and 9 months. Further details on the recruitment and assessment are described in the protocol.<sup>21</sup> Approval was obtained from Brunel University London's Research Ethics Committee. Participants gave informed written consent prior to completing the baseline assessment.

Following baseline assessments, participants were randomly allocated to the intervention or usual care control group in a 1:1 ratio. Allocation was performed by an individual independent to the study according to a computer-generated random schedule in random permuted blocks of 2 or 4. The allocation sequence was placed in sequentially numbered, opaque, sealed envelopes. Following each baseline assessment, an envelope was drawn sequentially by a researcher who informed the participant of their group allocation.

Participants and therapists were not blind to group allocation. Although assessors were also not blind, self-reported questionnaires were used and participants received standardised instructions to minimise detection bias. Assessment of objective PA and sedentary behaviour is unlikely to be influenced by the assessor being aware of group allocation. Data were processed and analysed by a researcher blind to group allocation.

### Intervention

Participants in the intervention group received four face-to-face sessions, each lasting 30–45 minutes, with a physiotherapist at the centre over 3 months, supported by a handbook and Yamax SW-200 Digi-Walker pedometer.<sup>22</sup> The intervention, which was delivered by four therapists, is described in the protocol<sup>21</sup> and Supplemental Material. Briefly, physiotherapists discussed increasing PA and step-count and reducing sedentary behaviour with participants using behaviour-change techniques,<sup>23</sup> guided by the handbook. The handbook contained pre-reading and reflection to be completed by the participant prior to each session. Therapists received a specific handbook with additional comments. Participants set and recorded PA, sedentary behaviour, and step-count goals in sessions 1–3, and monitored and recorded these behaviours between sessions using diaries included in the handbook (examples provided in Supplemental Material). Therapists received three half-day training sessions led by a behaviour-change technique trainer; two prior to delivering the intervention and one feedback session after they had each completed at least one intervention session. We video-recorded an example of the trainer delivering a session to a person with MS on our advisory group and

used this to support training. The trainer reviewed audio-recordings of one session for each therapist and provided feedback on this in the third training session. Brief cognitive-behavioural strategies, which were targeted at addressing perceived stress and coping with negative emotions in relation to adjusting to MS,<sup>24</sup> were included in both the training and handbook.

### *Procedures*

Data on sociodemographic characteristics, MS-specific characteristics, anthropometric measures, and the MS Impact Scale were collected at baseline.

Safety was determined by assessing pain, using the pain item on the EQ-5D-5L, and fatigue, using the Modified Fatigue Impact Scale (MFIS), at each assessment. The EQ-5D-5L asks people to identify the best description of their pain on a 5-point scale, from no pain or discomfort to extreme pain or discomfort. The EQ-5D-5L is linearly related to Kurtzke Expanded Disability Status Scale (EDSS) score in people with mild-to-moderate disability.<sup>25</sup> Specifically, the pain item on the EQ-5D-5L demonstrates excellent discriminatory capacity and no ceiling effect among people with MS.<sup>25</sup> At 3 and 9 months, participants were asked if they had experienced a fall, relapse or other AE, the number of events experienced, and a description of the event, using standardised questioning.

Moderate-to-vigorous physical activity (MVPA) and step-count were measured with the Actigraph GT3X accelerometer. Non-wear-time was defined as  $\geq 90$  consecutive minutes of 0 counts<sup>26</sup> and validated against participants' wear-time diaries. Participants with at least 3 days of 10 hours wear-time were included in analysis.<sup>27</sup> MVPA was indicated by a cut-point of  $\geq 1745$  counts/minute.<sup>28</sup> Sedentary (sitting and lying), standing and stepping time, respectively, were measured using the activPAL3 $\mu$  activity monitor, which was worn on the person's thigh for 7 days. Identification of non-wear time is described in Supplemental Material. Participants had at least 2 days of 10 hours of wear-time.

Self-reported time in moderate, vigorous, and walking activity were assessed using the International Physical Activity Questionnaire short-form. Walking capability was assessed using the Twelve Item MS Walking Scale (MSWS-12); higher scores indicated poorer walking capability. Fatigue was assessed using the MFIS; higher scores indicated greater impact of fatigue on a person's activities.


Self-efficacy was assessed using the Multiple Sclerosis Self-Efficacy Scale (MSSE); higher scores indicated higher self-efficacy. Participation over four domains (autonomy indoors, family role, autonomy outdoors, social life and relationships) was assessed using the Impact on Participation and Autonomy Questionnaire (IPA); higher scores represented poorer participation. Data on health service use over 9 months was obtained using a modified version of the Client Service Receipt Inventory (CSRI). Information on psychometric properties of measures is provided in the protocol.<sup>21</sup>

Feasibility of training therapists and therapists' experience of delivering the intervention was assessed by recording attendance at training sessions and via a focus group. Informed consent was obtained from therapists prior to conducting the focus group. A random selection of each therapists' sessions were audio-recorded. Fidelity to intervention content and delivery skills was assessed by one person using a standardised tool.<sup>21</sup> Percentage of expected content delivered was assessed;  $\geq 70\%$  was deemed acceptable.<sup>21</sup> Therapists' use of seven key skills, including empathic listening, partnership working and use of open-ended questions was rated as competent or not.

Fidelity to programme receipt and programme task, respectively, were evaluated through attendance at sessions and percentage of sections completed in the handbook, including diaries. Semi-structured interviews were conducted with 15 and 10 participants from the intervention and control groups, respectively, to explore acceptability of the intervention and feasibility of a definitive trial.

### *Data analysis*

Primary analyses were intention-to-treat. Secondary 'per-protocol' analyses were conducted using data from participants who attended  $\geq 75\%$  of intervention sessions and completed follow-up to 9 months. Analyses were conducted using Stata (version 15.0). To examine the effect and safety of the intervention, mean scores were compared between groups, at 3 and 9 months, respectively, using analysis of covariance adjusting for baseline score, and gender and type of MS as groups were unbalanced on these baseline characteristics. Logistic regression was used to compare the number of people with an AE at 9 months between groups. A negative binomial model, which accounts for overdispersion in the outcome, was used to compare the incidence of AEs over 9 months between groups. The focus group and interviews were analysed through Framework Analysis.<sup>29</sup>



**Figure 1.** Participant flow diagram.

## Results

Sixty people were randomly allocated to receive the intervention or usual care (Figure 1). The groups were mostly similar on baseline characteristics (Table 1). There were more women and more people with relapsing remitting MS in the control group. More people in the intervention group had secondary progressive MS. Outcomes at baseline are described in Table 2. Twenty-nine participants (97%) attended at least 75% of sessions. Fifty-five (92%) and 52 people (87%) attended the 3- and 9-month assessments. Health service use in both groups over 9 months is described in Supplemental Material. Activity data were obtained from between 84% and 93% of participants (Tables 2 and 3). Wear-time for activity monitors is presented in Supplemental Material.

## Safety

Fatigue was lower in the intervention group at 3 (mean difference (MD):  $-6.19$ , 95% CI  $-12.06$  to  $-0.31$ ) and 9 months (MD:  $-8.97$ , 95% CI  $-16.21$  to

$-1.72$ ; Table 4). There was no difference in pain between groups at 3 months (MD:  $-0.20$ , 95% CI  $-0.56$  to  $0.17$ ). Pain was lower in the intervention group at 9 months (MD:  $-0.53$ , 95% CI  $-0.96$  to  $-0.10$ ). Twenty-two participants in each group experienced at least one AE (Table 5). There was no difference between groups in the proportion of people who experienced an AE (odds ratio 0.83, 95% CI 0.22 to 3.14,  $p = 0.788$ ) or the incidence of an AE (rate ratio 0.98, 95% CI 0.47 to 2.07,  $p = 0.965$ ). Two participants in the intervention group experienced unrelated serious AEs; one person was admitted to hospital for a planned procedure and another person was admitted to hospital with pleurisy.

## Feasibility and acceptability

Training was deemed adequate in relation to content and approach. The therapists' handbook, use of a videoed example of delivering a session, and feedback on their delivery of the first face-to-face session

**Table 1.** Baseline characteristics.

	Usual care control group ( <i>n</i> = 30)			Intervention group ( <i>n</i> = 30)		
	<i>n</i> (%)	Mean (SD)	Median (range)	<i>n</i> (%)	Mean (SD)	Median (range)
Age, years	30	56.7 (9.2)	58 (37–72)	30	56.9 (9.0)	57 (39–74)
Women	24 (80)	–	–	17 (56.7)	–	–
Ethnicity						
White	25 (84)	–	–	27 (90)	–	–
Black	4 (13)	–	–	1 (3)	–	–
Asian	1 (3)	–	–	2 (7)	–	–
BMI, kg.m <sup>-2</sup>	30	26.3 (5.9)	26.5 (16.8–48.0)	30	25.9 (5.3)	23.8 (17.8–39.6)
Type of MS						
Relapsing-remitting	13 (43)	–	–	8 (27)	–	–
Secondary progressive	6 (20)	–	–	15 (50)	–	–
Primary progressive	8 (27)	–	–	6 (20)	–	–
Unknown	3 (10)	–	–	1 (3)	–	–
Relapse in past 12 months	14 (47)	–	–	14 (47)	–	–
MS duration, years	30	13.7 (9.4)	12.5 (1–33)	29	16.1 (10.5)	12.0 (2–42)
EDSS						
1.0–4.0	8 (27)	–	–	8 (27)	–	–
4.5–6.5	22 (73)	–	–	22 (73)	–	–
Mobility aid use over 5 m						
No aid	13 (43)	–	–	12 (40)	–	–
Sticks or crutches (one or two)	16 (54)	–	–	14 (47)	–	–
Walker or frame	1 (3)	–	–	4 (13)	–	–
MSIS-29 total	30	77.3 (39.8)	79.8 (14.6–172.4)	30	72.4 (35.0)	67.5 (10.3–141.8)
MSIS-29 physical	30	43.9 (19.9)	46.3 (3.8–86.3)	30	42.7 (22.5)	40 (3.8–86.3)
MSIS-29 psychological	30	33.3 (23.3)	30.6 (0–86.1)	30	29.7 (16.2)	30.6 (2.8–69.4)

SD: standard deviation; BMI: body mass index; MS: multiple sclerosis; EDSS: Kurtzke Expanded Disability Status Scale; MSIS: multiple sclerosis impact scale.

were particularly valued. Therapists reported that the programme was feasible to deliver within their current workload, although flexibility around timing of sessions and time for familiarisation was required. This required a commitment to invest ‘out of study’ time to consolidate their own learning and peer-support to clarify aspects between and after sessions, which improved their confidence to deliver the intervention.

Fidelity to content delivery was  $\geq 70\%$  for all sessions (range 89%–98%). All therapists were rated as competent across key delivery skills. Median completion of the handbook was 86.7% (range 23.3%–100%); 75% of participants completed  $\geq 70\%$  of the handbook. While overall, the handbook was both well received and deemed useful, some participants suggested improvements to the usability of the handbook. These included an online version, a reduction in some of the pre-session content and clearer signposting between sections. Indicative quotes representing its

acceptability and these suggestions are provided in Supplemental Material.

Participants with MS found the length of intervention, and frequency and length of sessions acceptable. Intervention structure and therapist continuity facilitated the development of a supportive participant-therapist relationship, which fostered a sense of relatedness and autonomy that was crucial to enhance self-efficacy for PA engagement. Self-management strategies such as pacing, goal-setting, setting graded tasks, self-monitoring and action-planning were well received. More detail on participants’ experiences of the intervention is presented elsewhere.<sup>30</sup>

The pedometer provided visual, objective feedback, which enhanced participants’ awareness of and motivation to increase PA. However, eight participants reported issues with attachment and accuracy of the pedometer, two expressed a desire for a monitor that could measure MVPA in addition to step-count, six

**Table 2.** Description of outcomes at baseline.

	Usual care control group ( <i>n</i> = 30)			Intervention group ( <i>n</i> = 30)		
	<i>n</i>	Mean (SD)	Median (range)	<i>n</i>	Mean (SD)	Median (range)
Daily step-count	28	3476.0 (2383.7)	2504.6 (546.4–10265.7)	30	3334.7 (2384.7)	2639.0 (183.4–10350.9)
Daily MVPA, min	28	17.6 (15.5)	11.7 (1.0–52.7)	30	18.3 (17.1)	11.6 (1.5–65.7)
Daily sedentary time, hr	26	9.6 (1.5)	9.8 (6.8–12.5)	30	10.5 (2.0)	10.4 (6.8–14.5)
Daily standing time, hr	26	4.2 (1.4)	4.2 (1.9–6.7)	30	3.6 (1.7)	3.7 (0.3–7.1)
Daily stepping time, hr	26	1.2 (0.7)	1.1 (0.01–2.6)	30	1.1 (0.7)	1.0 (0.05–2.8)
Daily self-reported walking time, min	30	43.9 (60.6)	15 (0–190)	30	43.7 (85.3)	7.5 (0–385.7)
Daily self-reported MVPA, min	30	25 (35.1)	14.3 (0–120)	30	9.4 (20.1)	1.4 (0–77.1)
MSWS-12 total score, %	30	75.4 (17.6)	77.5 (20–100)	30	73.9 (22.1)	82.5 (26.7–100)
MFIS total score (score 0–84)	30	42.3 (18.1)	43.5 (3–72)	30	44.2 (19.1)	45.5 (1–81)
EQ-5D-5L pain question (score 1–5)	30	2.4 (1.0)	2 (1–4)	30	2.3 (1.1)	2 (1–5)
MSSE total score (score 10–100)	30	67.2 (21.2)	67.2 (33.3–99.4)	30	69.6 (21.2)	74.4 (22.8–98.9)
IPA: autonomy indoors (score 0–4)	30	0.6 (0.8)	0 (0–2)	30	0.8 (0.9)	0 (0–3)
IPA: autonomy outdoors (score 0–4)	30	1.7 (1.1)	1.5 (0–4)	30	1.5 (1.2)	1 (0–3)
IPA: family role (score 0–4)	30	1.3 (0.9)	1 (0–3)	30	1.3 (1.1)	1 (0–3)
IPA: social life and relationships (score 0–4)	30	0.4 (0.5)	0 (0–1)	30	0.5 (0.7)	0 (0–2)

MVPA: moderate-to-vigorous physical activity; MSWS-12: Twelve Item MS Walking Scale; MFIS: Modified Fatigue Impact Scale; MSSE: Multiple Sclerosis Self-Efficacy Scale; IPA: Impact on Participation and Autonomy Questionnaire.

purchased an alternative monitor, and two used their phone to measure step-count.

#### *Feasibility of definitive trial*

Communication with the research team was acceptable to participants. Study information was deemed adequate, and understanding among participants about the randomisation process was good. Participants found the assessment process acceptable. In general, activity monitoring was well-tolerated. Specific issues with the Actigraph included forgetting to attach it (*n* = 6), discomfort caused by the waistband or from the monitor shifting position (*n* = 5), and difficulty removing the monitor in relation to bladder urgency (*n* = 3). Skin irritation from wearing the activPAL3 $\mu$ , visibility of the activPAL3 $\mu$  under clothing, and the intrusiveness of wearing the monitor at night were each mentioned by one participant, respectively.

#### *Effects*

Results from intention-to-treat analysis are presented in Tables 3 and 4. There was no difference in sedentary time, step-count, MVPA, or self-reported walking or MVPA between groups. Stepping time differed between groups at 3 (MD: 0.17 hr, 95% CI 0.04–0.31)

and 9 months (MD: 0.27 hr, 95% CI 0.06–0.48), in favour of the intervention group. In addition to improvements in fatigue and pain (Table 4), there were between-group difference in scores for MSWS-12 (MD: –7.11, 95% CI –14.04 to –0.19) at 3 months, and MSSE (MD: 9.10, 95% CI 0.39–17.81), autonomy indoors (MD: –0.36, 95% CI –0.69 to –0.04) and autonomy outdoors (MD: –0.46, 95% CI –0.90 to –0.02) at 9 months, in favour of the intervention group. Results from per-protocol analyses were nearly identical (Supplemental Material).

#### **Discussion**

Findings show that a physiotherapist-led behaviour-change intervention of four face-to-face sessions supported by a handbook and pedometer was safe, feasible and acceptable to people with MS. The following criteria were proposed a priori to determine whether the intervention warrants further evaluation in a larger trial:<sup>21</sup> no evidence of a greater number of AEs or greater negative change in pain and fatigue in the intervention group in comparison to the control group; no indication of a dominant negative theme from interviews with participants and physiotherapists; attrition rate < 20%. We found no evidence that the rate of AEs differed between groups or that pain or fatigue was higher in the intervention group at 3 or 9 months. Although the proportion of participants who experienced an AE was relatively high

**Table 3.** Differences in physical activity and sedentary behaviour outcomes between groups at 3 and 9 months.

	Control group ( <i>n</i> = 30)	Intervention group ( <i>n</i> = 30)	Difference in means <sup>a</sup> (95% CI); <i>p</i> value
<b>Daily step-count</b>			
Mean (SD) at 3 months	3618.9 (2168.0)	3560.1 (2506.1)	211.62 (−378.69 to 801.93); 0.473
Number (%) assessed	21 (70%)	26 (87%)	
Mean (SD) at 9 months	3781.0 (2743.6)	3798.2 (2988.8)	543.27 (−223.01 to 1309.55); 0.160
Number (%) assessed	21 (70%)	26 (87%)	
<b>Daily moderate-to-vigorous activity, min</b>			
Mean (SD) at 3 months	17.9 (15.4)	16.9 (16.1)	−1.51 (−6.95 to 3.94); 0.579
Number (%) assessed	21 (70%)	26 (87%)	
Mean (SD) at 9 months	19.3 (16.7)	20.3 (22.4)	4.68 (−3.37 to 12.93); 0.247
Number (%) assessed	21 (70%)	26 (87%)	
<b>Daily sedentary time, hr</b>			
Mean (SD) at 3 months	9.2 (1.7)	9.6 (2.3)	−0.53 (−1.14 to 0.07); 0.080
Number (%) assessed	22 (73%)	24 (80%)	
Mean (SD) at 9 months	8.9 (1.9)	9.7 (2.2)	0.13 (−0.80 to 1.06); 0.772
Number (%) assessed	19 (63%)	26 (87%)	
<b>Daily standing time, hr</b>			
Mean (SD) at 3 months	4.2 (1.5)	4.0 (2.0)	0.36 (−0.27 to 1.00); 0.256
Number (%) assessed	22 (73%)	24 (80%)	
Mean (SD) at 9 months	4.5 (1.8)	4.2 (1.9)	0.23 (−0.47 to 0.93); 0.515
Number (%) assessed	19 (63%)	26 (87%)	
<b>Daily stepping time, hr</b>			
Mean (SD) at 3 months	1.2 (0.6)	1.2 (0.8)	0.17 (0.04 to 0.31); 0.012 <sup>b</sup>
Number (%) assessed	22 (73%)	24 (80%)	
Mean (SD) at 9 months	1.2 (0.7)	1.2 (0.8)	0.27 (0.06 to 0.48); 0.012
Number (%) assessed	19 (63%)	26 (87%)	
<b>Daily self-reported walking time, min</b>			
Mean (SD) at 3 months	49.6 (92.1)	35.9 (43.6)	−15.14 (−57.13 to 26.86); 0.472
Number (%) assessed	27 (90%)	28 (93%)	
Mean (SD) at 9 months	26.5 (35.6)	48.0 (77.3)	37.42 (−3.33 to 78.18); 0.071 <sup>b</sup>
Number (%) assessed	25 (83%)	27 (90%)	
<b>Daily self-reported moderate-to-vigorous activity, min</b>			
Mean (SD) at 3 months	19.7 (40.3)	7.2 (11.3)	−2.85 (−18.46 to 12.76); 0.715
Number (%) assessed	27 (90%)	28 (93%)	
Mean (SD) at 9 months	9.6 (12.5)	5.2 (6.9)	−4.13 (−10.85 to 2.58); 0.221
Number (%) assessed	25 (83%)	27 (90%)	

CI: confidence interval.

<sup>a</sup>Adjusted for baseline values, gender and type of multiple sclerosis.<sup>b</sup>Robust standard errors used as evidence of heteroscedasticity.

in both groups, this may be because we systematically assessed AEs, regardless of their relatedness. Reporting of AEs in studies of behaviour-change interventions for people with MS has been poor to date with many not reporting information on AEs or not describing how AEs were assessed.

Focus groups with therapists and interviews with participants indicated that the intervention was feasible

to deliver and acceptable to receive. However, therapists committed additional time to consolidating their learning outside of formal training sessions and this likely contributed to the successful implementation of the intervention. Furthermore, therapists used peer-support to clarify aspects between and after sessions, and consequently build their confidence. Therapists working in isolation may find it more difficult to deliver the intervention.

**Table 4.** Differences in walking capability (MSWS-12), fatigue (MFIS), pain (EQ-5D-5L), self-efficacy (MSSE) and participation (IPA) between groups at 3 and 9 months.

	Control group ( <i>n</i> = 30)	Intervention group ( <i>n</i> = 30)	Difference in means <sup>a</sup> (95% CI); <i>p</i> value
<b>MSWS-12 total score, %</b>			
Mean (SD) at 3 months	72.1 (19.0)	64.9 (22.6)	-7.11 (-14.04 to -0.19); 0.044
Number (%) assessed	27 (90%)	28 (93%)	
Mean (SD) at 9 months	72.4 (18.8)	68.1 (23.9)	-6.57 (-14.71 to 1.57); 0.111
Number (%) assessed	25 (83%)	27 (90%)	
<b>MFIS total score (score 0 to 84)</b>			
Mean (SD) at 3 months	39.1 (16.0)	36.3 (15.5)	-6.19 (-12.06 to -0.31); 0.039
Number (%) assessed	27 (90%)	28 (93%)	
Mean (SD) at 9 months	42.0 (15.2)	35.6 (15.0)	-8.97 (-16.21 to -1.72); 0.016
Number (%) assessed	25 (83%)	27 (90%)	
<b>EQ-5D-5L pain question (score 1 to 5)</b>			
Mean (SD) at 3 months	2.3 (0.9)	2.0 (0.7)	-0.2 (-0.6 to 0.2); 0.286
Number (%) assessed	27 (90%)	28 (93%)	
Mean (SD) at 9 months	2.4 (1.0)	2.0 (0.8)	-0.5 (-1.0 to -0.1); 0.017
Number (%) assessed	25 (83%)	27 (90%)	
<b>MSSE total score (score 10 to 100)</b>			
Mean (SD) at 3 months	68.3 (20.5)	75.2 (19.6)	6.92 (-0.58 to 14.42); 0.070
Number (%) assessed	27 (90%)	28 (93%)	
Mean (SD) at 9 months	68.3 (20.4)	76.0 (20.1)	9.10 (0.39 to 17.81); 0.041
Number (%) assessed	25 (83%)	27 (90%)	
<b>IPA: autonomy indoors (score 0 to 4)</b>			
Mean (SD) at 3 months	0.7 (1.0)	0.5 (0.8)	-0.28 (-0.68 to 0.11); 0.159
Number (%) assessed	27 (90%)	28 (93%)	
Mean (SD) at 9 months	0.6 (0.7)	0.4 (0.8)	-0.36 (-0.69 to -0.04); 0.028
Number (%) assessed	25 (83%)	27 (90%)	
<b>IPA: autonomy outdoors (score 0 to 4)</b>			
Mean (SD) at 3 months	1.5 (1.1)	1.2 (1.0)	-0.16 (-0.62 to 0.31); 0.501
Number (%) assessed	27 (90%)	28 (93%)	
Mean (SD) at 9 months	1.5 (1.1)	1.1 (1.0)	-0.46 (-0.90 to -0.02); 0.039
Number (%) assessed	25 (83%)	27 (90%)	
<b>IPA: family role (score 0 to 4)</b>			
Mean (SD) at 3 months	1.4 (1.1)	1.0 (1.1)	-0.43 (-1.06 to 0.20); 0.172
Number (%) assessed	27 (90%)	28 (93%)	
Mean (SD) at 9 months	1.3 (1.0)	1.0 (0.9)	-0.31 (-0.80 to 0.18); 0.211
Number (%) assessed	25 (83%)	27 (90%)	
<b>IPA: social life and relationships (score 0 to 4)</b>			
Mean (SD) at 3 months	0.5 (0.6)	0.4 (0.6)	-0.15 (-0.45 to 0.15); 0.329
Number (%) assessed	27 (90%)	28 (93%)	
Mean (SD) at 9 months	0.4 (0.6)	0.4 (0.6)	-0.23 (-0.53 to 0.06); 0.113
Number (%) assessed	25 (83%)	27 (90%)	

CI: confidence interval; MSWS-12: Twelve Item MS Walking Scale; MFIS: Modified Fatigue Impact Scale; MSSE: Multiple Sclerosis Self-Efficacy Scale; IPA: Impact on Participation and Autonomy Questionnaire.  
<sup>a</sup>Adjusted for baseline values, gender and type of multiple sclerosis.

Some amendments to intervention components are recommended prior to further evaluation. Some participants documented aspects covered in the handbook, specifically monitoring, in self-designed

electronic spreadsheets. These were not included in the assessment of fidelity suggesting we underestimated handbook completion. The choice to document elsewhere as well as some people's requests for

**Table 5.** Adverse events.

	Control group ( <i>n</i> = 30)	Intervention group ( <i>n</i> = 30)
Number with any adverse event, <i>n</i> (%)	22 (73%)	22 (73%)
Cause of adverse event <sup>a</sup>		
Fall	16 (53%)	16 (53%)
Fall resulting in injury	12 (40%)	11 (37%)
Relapse	6 (20%)	2 (7%)
Cold	3 (10%)	4 (13%)
Urinary tract infection	1 (3%)	3 (10%)
Chest infection or cough	2 (7%)	3 (10%)
Increased lower-limb pain	5 (17%)	1 (3%)
Increased back pain	0 (0%)	2 (7%)
Worsening mobility	3 (10%)	1 (3%)
Increased spasticity	3 (10%)	0 (0%)
Worsening sensory impairment	1 (3%)	2 (7%)
Incidence of adverse events per person, median (range)	2 (0–53)	3 (0–43)
Cause of adverse event <sup>a</sup>		
Fall	1 (0–50)	1 (0–43)
Fall resulting in injury	0 (0–3)	0 (0–5)
Relapse	0 (0–2)	0 (0–1)
Chest infection or cough	0 (0–2)	0 (0–1)
Increased back pain	0 (0–0)	0 (0–3)
Increased spasticity	0 (0–2)	0 (0–0)

<sup>a</sup>Reported where adverse event experienced by > 1 participant.

an online version of the handbook suggests an online version is required. However, there was no consensus regarding the ‘best’ format, and alternative formats may be required depending on participant choice. While some participants suggested reducing pre-session content, the level of information required may depend on the individual. Clearer signposting between sections may improve the usability of the handbook without the need to reduce content. Although the pedometer was previously validated among adults with MS, several participants reported difficulties using it and doubts regarding its accuracy. As no study has examined the acceptability of behaviour-change interventions that incorporate an activity monitor for people with MS, it is unclear if these issues are specific to our sample or apply to the MS population more broadly. In addition, the ability to monitor MVPA may contribute to greater changes in MVPA. However, the cost and accuracy of such a monitor needs to be considered against potential benefits.

Although the intervention was less intensive than other behaviour-change interventions in the literature,<sup>31</sup> it was delivered face-to-face, on a one-to-one

basis, unlike previous interventions that delivered group sessions,<sup>32,33</sup> or delivered telephone<sup>20,14</sup> or Internet interventions.<sup>17–19</sup> Participants emphasised the strong therapeutic relationship was key to developing confidence and competence for PA enactment. Therefore, the potential challenges of delivering face-to-face sessions should be balanced against the benefits of a relatively low-resource intervention.

Attrition was low at 3 and 9 months and missing data were minimal. Although a small number of participants reported issues with wearing the monitors such as forgetting to attach them or discomfort, monitoring was generally well-tolerated. The proportion of missing data was higher for activity monitors compared with other outcome measures, but not higher than levels of missing data reported in similar trials involving activity monitoring.<sup>34</sup> Given we found objective measurement of PA and sedentary behaviour to be acceptable, and that it is recommended over self-report,<sup>8</sup> we believe that accelerometers should be used in future trials examining effectiveness of behaviour-change interventions on PA and sedentary behaviour. However, the potential for up to 15% missing data should be considered when determining sample size.

We found no evidence of between-group differences in step-count, MVPA or sedentary behaviour at 3 or 9 months. However, our analysis was likely underpowered. Based on the standard deviation of 2400 steps/day observed in our sample at baseline, we estimate a sample of 382 individuals is required to detect a between-group difference of 800 steps/day at 3 months with 90% power and 5% significance. Only one study has found a positive effect on objectively measured PA among people with MS. Carter observed a between-group difference of 688.5 steps/day in favour of the intervention following a 3 month intervention, but no difference at 9 months.<sup>1</sup> We observed a positive treatment effect on fatigue at 3 and 9 months. In contrast, a meta-analysis of behaviour-change interventions reported no effect on fatigue,<sup>31</sup> despite many of the interventions specifically targeting fatigue management.<sup>35–38</sup> We also found between-group differences in self-efficacy, walking capability and participation at 9 months. Although a measure of PA self-efficacy may be more sensitive to change following the intervention, the MSSE includes a number of items such as confidence in ability to mobilise, complete activities of daily living, and manage symptoms of MS, which we believe are important to evaluate when determining the effects of a behaviour-change intervention.

There are limitations to this study. We used the pain item on the EQ-5D-5L to assess bodily pain as we were unable to identify an instrument that specifically measured bodily pain in people with MS. Although the pain item on the EQ-5D-5L demonstrates excellent discriminatory capacity among people with MS,<sup>25</sup> it may provide only a crude indication of pain and does not provide information about pain frequency. Although we attempted to be as inclusive as possible by not indicating a specific distance that individuals should be able to walk for, findings are not generalisable to non-ambulatory individuals. Similarly, participants were largely recruited from a single MS Therapy Centre and thus may not be representative of the wider population of adults with MS in England. The effect of the intervention on an objective measure of function such as a timed walk test was not assessed because we were unable to conduct such a test in participants' homes. Analysis of efficacy was preliminary and should be interpreted with caution. The analysis lacked statistical power and the lack of an active comparator and blinding of participants potentially inflated the observed treatment effect. While there is currently no evidence as to what constitutes best practice to increase PA and reduce sedentary behaviour among people with MS, some form of active comparator

should be included in a trial of clinical-effectiveness in order to control for the effect of attention and placebo on outcomes.

In summary, our results show that a behaviour-change intervention to increase PA and reduce sedentary behaviour in people with MS was safe, feasible, acceptable, and showed some positive effects. Comparison of findings against pre-determined criteria indicates that the intervention warrants further evaluation to determine effectiveness on PA and sedentary behaviour.

#### Authors' Note

Trial registration: Changing physical activity behaviour in people with MS: the iStep-MS trial; <https://doi.org/10.1186/ISRCTN15343862>; ISRCTN15343862.

#### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

#### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the MS Society UK (grant number 53).

#### Supplemental material

Supplemental material for this article is available online.

#### References

1. Carter A, Daley A, Humphreys L, et al. Pragmatic intervention for increasing self-directed exercise behaviour and improving important health outcomes in people with multiple sclerosis: A randomised controlled trial. *Mult Scler* 2014; 20(8): 1112–1122.
2. Grover SA, Aubert-Broche B, Fetco D, et al. Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis. *Neurology* 2015; 85(19): 1663–1669.
3. Tallner A, Waschbisch A, Hentschke C, et al. Mental health in multiple sclerosis patients without limitation of physical function: The role of physical activity. *Int J Mol Sci* 2015; 16(7): 14901–14911.
4. Hubbard EA, Motl RW and Manns PJ. The descriptive epidemiology of daily sitting time as a sedentary behavior in multiple sclerosis. *Disabil Health J* 2015; 8(4): 594–601.

5. Sandroff BM, Dlugonski D, Weikert M, et al. Physical activity and multiple sclerosis: New insights regarding inactivity. *Acta Neurol Scand* 2012; 126(4): 256–262.
6. Casey B, Coote S, Hayes S, et al. Changing physical activity behavior in people with multiple sclerosis: A systematic review and meta-analysis. *Arch Phys Med Rehabil* 2018; 99(10): 2059–2075.
7. Prince SA, Adamo KB, Hamel ME, et al. A comparison of direct versus self-report measures for assessing physical activity in adults: A systematic review. *Int J Behav Nutr Phys Act* 2008; 5: 56.
8. Steene-Johannessen J, Anderssen SA, van der Ploeg HP, et al. Are self-report measures able to define individuals as physically active or inactive? *Med Sci Sports Exerc* 2016; 48(2): 235–244.
9. Sikes EM, Richardson EV, Cederberg KJ, et al. Use of the Godin Leisure-Time Exercise Questionnaire in multiple sclerosis research: A comprehensive narrative review. *Disabil Rehabil* 2019; 41(11): 1243–1267.
10. Klaren RE, Hubbard EA and Motl RW. Efficacy of a behavioral intervention for reducing sedentary behavior in persons with multiple sclerosis: A pilot examination. *Am J Prev Med* 2014; 47(5): 613–616.
11. Bull FC and The Expert Working Groups. Physical activity guidelines in the U.K.: Review and recommendations. Technical report, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, May 2010.
12. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: The new Medical Research Council guidance. *BMJ* 2008; 337: a1655.
13. Hayes S, Uszynski MK, Motl RW, et al. Randomised controlled pilot trial of an exercise plus behaviour change intervention in people with multiple sclerosis: The Step It Up study. *BMJ Open* 2017; 7(10): e016336.
14. Bombardier CH, Cunniffe M, Wadhvani R, et al. The efficacy of telephone counseling for health promotion in people with multiple sclerosis: A randomized controlled trial. *Arch Phys Med Rehabil* 2008; 89(10): 1849–1856.
15. Dlugonski D, Motl RW, Mohr DC, et al. Internet-delivered behavioral intervention to increase physical activity in persons with multiple sclerosis: Sustainability and secondary outcomes. *Psychol Health Med* 2012; 17(6): 636–651.
16. Carter AM, Daley AJ, Kesterton SW, et al. Pragmatic exercise intervention in people with mild to moderate multiple sclerosis: A randomised controlled feasibility study. *Contemp Clin Trials* 2013; 35(2): 40–47.
17. Motl RW, Dlugonski D, Wojcicki TR, et al. Internet intervention for increasing physical activity in persons with multiple sclerosis. *Mult Scler* 2011; 17(1): 116–128.
18. Pilutti LA, Dlugonski D, Sandroff BM, et al. Randomized controlled trial of a behavioral intervention targeting symptoms and physical activity in multiple sclerosis. *Mult Scler* 2014; 20(5): 594–601.
19. Sandroff BM, Klaren RE, Pilutti LA, et al. Randomized controlled trial of physical activity, cognition, and walking in multiple sclerosis. *J Neurol* 2014; 261(2): 363–372.
20. Rice IM, Rice LA and Motl RW. Promoting physical activity through a manual wheelchair propulsion intervention in persons with multiple sclerosis. *Arch Phys Med Rehabil* 2015; 96(10): 1850–1858.
21. Ryan JM, Fortune J, Stennett A, et al. Changing physical activity behaviour for people with multiple sclerosis: Protocol of a randomised controlled feasibility trial (iStep-MS). *BMJ Open* 2017; 7(11): e018875.
22. Motl RW, McAuley E, Snook EM, et al. Validity of physical activity measures in ambulatory individuals with multiple sclerosis. *Disabil Rehabil* 2006; 28(18): 1151–1156.
23. Michie S, Ashford S, Sniehotta FF, et al. A refined taxonomy of behaviour change techniques to help people change their physical activity and healthy eating behaviours: The CALO-RE taxonomy. *Psychol Health* 2011; 26(11): 1479–1498.
24. Moss-Morris R, Dennison L, Landau S, et al. A randomized controlled trial of cognitive behavioral therapy (CBT) for adjusting to multiple sclerosis (the saMS trial): Does CBT work and for whom does it work? *J Consult Clin Psychol* 2013; 81(2): 251–262.
25. Fogarty E, Walsh C, Adams R, et al. Relating health-related quality of life to disability progression in multiple sclerosis, using the 5-level EQ-5D. *Mult Scler* 2013; 19(9): 1190–1196.
26. Choi L, Liu Z, Matthews CE, et al. Validation of accelerometer wear and nonwear time classification algorithm. *Med Sci Sports Exerc* 2011; 43(2): 357–364.
27. Motl RW, Zhu W, Park Y, et al. Reliability of scores from physical activity monitors in adults with multiple sclerosis. *Adapt Phys Activ Q* 2007; 24(3): 245–253.
28. Sandroff BM, Riskin BJ, Agiovlasis S, et al. Accelerometer cut-points derived during over-ground walking in persons with mild, moderate, and severe multiple sclerosis. *J Neurol Sci* 2014; 340(1–2): 50–57.
29. Ritchie J and Lewis J. *Qualitative research practice: A guide for social science students and researchers*. London: SAGE, 2009.

30. Fortune J, Norris M, Stennett A, et al. 'I can do this': A qualitative exploration of acceptability and experiences of a physical activity behaviour change intervention in people with multiple sclerosis in the UK. *BMJ Open* 2019; e029831.
31. Sangelaji B, Smith CM, Paul L, et al. The effectiveness of behaviour change interventions to increase physical activity participation in people with multiple sclerosis: A systematic review and meta-analysis. *Clin Rehabil* 2016; 30(6): 559–576.
32. Stuijbergen AK, Becker H, Blozis S, et al. A randomized clinical trial of a wellness intervention for women with multiple sclerosis. *Arch Phys Med Rehabil* 2003; 84(4): 467–476.
33. Coote S, Uszynski M, Herring MP, et al. Effect of exercising at minimum recommendations of the multiple sclerosis exercise guideline combined with structured education or attention control education – Secondary results of the step it up randomised controlled trial. *BMC Neurol* 2017; 17(1): 119.
34. Harris T, Kerry SM, Limb ES, et al. Effect of a primary care walking intervention with and without nurse support on physical activity levels in 45- to 75-year-olds: The Pedometer And Consultation Evaluation (PACE-UP) cluster randomised clinical trial. *PLoS Med* 2017; 14(1): e1002210.
35. Hugos CL, Copperman LF, Fuller BE, et al. Clinical trial of a formal group fatigue program in multiple sclerosis. *Mult Scler* 2010; 16(6): 724–732.
36. Garcia Jalon EG, Lennon S, Peoples L, et al. Energy conservation for fatigue management in multiple sclerosis: A pilot randomized controlled trial. *Clin Rehabil* 2013; 27(1): 63–74.
37. Mathiowetz VG, Finlayson ML, Matuska KM, et al. Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. *Mult Scler* 2005; 11(5): 592–601.
38. Rietberg MB, van Wegen EE, Eyssen IC, et al. Effects of multidisciplinary rehabilitation on chronic fatigue in multiple sclerosis: A randomized controlled trial. *PLoS ONE* 2014; 9(9): e107710.